Navigation Links
Apollo Endosurgery Completes First Clinical Case with Newly-Launched FlexShears™ Endoscopic Scissors
Date:10/11/2010

AUSTIN, Texas, Oct. 11 /PRNewswire/ -- Apollo Endosurgery, Inc. announced completion of the first clinical case involving its FlexShears™ Endoscopic Scissors.  The new device was used to cut and remove an obstructing eroded suture from the patient's GI tract in a procedure that embodies the Apollo vision of improving patient care with flexible surgery.

The subject of the case had undergone a Roux-en-Y gastric bypass surgery in 2001, and subsequently had suffered from protracted obstructive symptoms.  A recent EGD performed to evaluate the patient's obstructive symptoms identified an eroded non-absorbable suture traversing the mid-lumen immediately distal to the gastric pouch as the probable cause.

"The thinking was that an open surgical procedure to remove the suture would be the likely next step," said the patient.

Wishing to avoid a subsequent surgery and the complications that can follow, the patient — himself a retired surgeon — began researching alternative therapies. An article in Obesity Surgery on the utility of endoscopic scissors in removing endolumenal sutures led the patient to the article's author, Dr. Subhas Banerjee, (Director of Endoscopy, Stanford Hospital) who was able treat the condition endoscopically.

The scissors used in prior suture removal cases conducted at Stanford were fragile and ill-suited to the application.  Aware of the pre-commercial availability of the FlexShears scissors — which incorporate novel blade technology and rotational ability — Dr. Banerjee contacted Apollo in preparation for the case.

Accessing the gastric pouch with a therapeutic gastroscope, the offending suture was readily identified and easily cut using the FlexShears scissors. In comments to Apollo's representative, Dr. Banerjee mentioned that the new scissors exceptional cutting ability and rotational capability provided a vast improvement over previous, similar devices.  

The entire procedure took only minutes and was performed under light, conscious sedation, enabling a quick recovery.  

Following the case "I was eating several hours later without difficulty and the procedure seems to have relieved nine and one-half years of obstructive [symptoms]", wrote the patient in a follow-up correspondence to Apollo.

The decreased invasiveness, cost and recovery time of this procedure compared to the surgical alternative demonstrates the patient care benefits that Apollo Endosurgery offers through the development and introduction of its flexible surgery devices.

For more information on the FlexShears Endoscopic Scissors and how Apollo Endosurgery is Defining the Future of Flexible Surgery™, visit our website:  www.apolloendo.com

About Apollo Endosurgery, Inc.Apollo Endosurgery, Inc. is dedicated to revolutionizing patient care through the development of flexible surgery, which is emerging from the convergence of laparoscopic surgery and therapeutic gastroenterology.  Flexible surgery minimizes the trauma of surgical access by taking advantage of natural orifices to deliver surgical tools to targeted areas.  All of Apollo's products are compatible with existing flexible endoscope platforms.  Apollo Endosurgery was co-founded with the Apollo Group, a unique collaboration of physicians from the Mayo Clinic, Johns Hopkins University, Medical University of South Carolina, the University of Texas Medical Branch and the Chinese University of Hong Kong.  The company is funded by PTV Sciences and H.I.G. Ventures.For more information, contact:Ted StephensDirector of MarketingApollo Endosurgery, Inc.(m)  513-312-9161(0)  512-328-9990, ext 225  www.apolloendo.com
'/>"/>

SOURCE Apollo Endosurgery, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
4. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
5. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
6. QuatRx Completes Patient Enrollment in Phase 3 Study of Ophena(TM) in Women with Postmenopausal Vaginal Syndrome
7. CryoCor Completes Enrollment of Pivotal Clinical Study for Atrial Fibrillation
8. Anesiva Completes Enrollment in Phase 3 Clinical Trial of Zingo(TM) to Treat Pain Associated With Venous Access Procedures in Adults
9. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
10. Cadence Pharmaceuticals Completes Enrollment of Pivotal Phase III Trial for Intravenous Acetaminophen Ahead of Schedule
11. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... , June 24, 2016 VolitionRx ... of Dr. Edward Futcher to the ... effective June 23, 2016.Dr. Futcher was also appointed ... Governance Committees.  As a non-executive member of the ... and strategic counsel to VolitionRx in connection with ...
(Date:6/23/2016)... June 23, 2016 Research and ... Excipients Market by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), ... Topical, Coating, Parenteral) - Global Forecast to 2021" ... The global pharmaceutical excipients market is projected ... CAGR of 6.1% in the forecast period 2016 to ...
(Date:6/23/2016)... June 23, 2016 Research and Markets ... Issue 52" report to their offering. ... treatment creates a favourable commercial environment for MedImmune to enter. ... base that will serve to drive considerable growth for effective ... serve to cap sales considerably, but development is still in ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson has ... he has implemented orthobiologic procedures as a method for treating his patients. The ... first doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published June ... with. The article goes on to state that individuals are now more comfortable seeking ... common operations such as calf and cheek reduction. The Los Angeles area medical group, ...
(Date:6/24/2016)... ... 24, 2016 , ... Marcy was in a crisis. Her son James, eight, was out of ... verbally and physically. , “When something upset him, he couldn’t control his emotions,” remembers Marcy. ... throw rocks at my other children and say he was going to kill them. ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. Amanda ... orthodontic treatment. Dr. Cheng has extensive experience with all areas of orthodontics, including ... accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. ...
(Date:6/24/2016)... , ... June 24, 2016 , ... People across the ... Genome magazine’s Code Talker Award, an essay contest in which patients and their families ... to be presented at the 2016 National Society of Genetic Counselors (NSGC) Annual Education ...
Breaking Medicine News(10 mins):